(29 Mar 2017-Hong Kong)Fullshare Holdings Limited (“Fullshare Holdings” or the “Company”; SEHK stock code: 607, together with its subsidiaries, the “Group”), is pleased to announce that on 29 March 2017, the Group entered into an non-legally binding memorandum of understanding (the “MOU”) with ICX Holding Limited(深圳碳雲控股有限公司; “ICX Holding”)to co-develop the healthcare market.

ICX Holding is a company controlled by Mr. Wang Jun, the founder and ultimate controller of iCarbonX (Shenzhen) Company Limited (深圳碳云智能科技有限公司). Mr. Wang Jun earned a bachelor’s degree in artificial intelligence and a Ph.D. in bioinformatics from Peking University. In 1999, Dr. Wang, co-founded BGI as CEO, which is now widely-recognized as one of world’s premier research facilities committed to excellence in genome sciences.

The ICX Holding is one of the company in the iCarbonX series and the controlling shareholder of iCarbonX (Shenzhen) Company Limited. As one of the most specialized health data consolidation platform in the PRC, the iCarbonX series aims to provide professional customized analysis and forecast on the health status of an individual through collecting genetic, biological, behavioral and psychological data via internet and artificial intelligence technologies. The analysis and forecasts are mainly used to bridge bespoke beauty, nutrition, health and medical treatment products and services in the healthcare industry.

Leverage on the Fullshare’s rich experiences in industrial operation, its well-established product and service channels and together with iCarbonX series’ expertise and resources in life and health science, the Group targets to build a platform with iCarbonX series to introduce healthcare related operations, advanced technologies and quality business targets through mergers and acquisitions.

Mr. Ji Changqun, Executive Director, Chairman and CEO of Fullshare Holdings Limited commented, “The Group is a conglomerate focusing on business operation. By consolidating resources in healthy living industry and forming strategic collaboration with leaders in different

industries, the Group endeavors to develop itself into a world-leading healthcare product and service provider. iCarbonX series is the front runner in the biological big data industry with solid medical and information technology background. Its data and analysis enable individuals to select suitable diagnostic, treatments and healthcare services, dietary suggestions, aesthetic treatments and many other services and products that tailor-made to his or her genetic and biological specification.”

Mr. Ji further stated, “The business of iCarbonX series is a strong complement to the Group’s medical and healthcare platform. By collaborating with iCarbonX series, the Group is capable to

provide tailor-made healthcare products, services and solutions according to the genetic and biological specification of each client. iCarbonX series may utilize the Group’s well-established product and service platforms to commercialize its data and online resources in offline markets. iCarbonX series and Fullshare would look for merger and acquisition opportunities in biological data mining, internet and artificial intelligence markets through the strategic cooperation. By introducing overseas companies and advanced technologies, together, the Group and iCarbonX series will create a comprehensive service and product chain in the healthcare and life technological industry.